Production of (177)Lu for Targeted Radionuclide Therapy: Available Options. - Wikidata - wikimedia - TriplyDB

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

http://www.wikidata.org/entity/Q35724907

about

Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab Radiolabeled bombesin derivatives for preclinical oncological imaging.Computational modeling of radiobiological effects in bone metastases for different radionuclides.Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.Radiolabeled Anti-Adenosine Triphosphate Synthase Monoclonal Antibody as a Theragnostic Agent Targeting Angiogenesis.Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model.Efficient Uptake of 177 Lu-Porphyrin-PEG Nanocomplexes by Tumor Mitochondria for Multimodal-Imaging-Guided Combination Therapy.Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.(90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with 64Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts.Inter-comparison of quantitative imaging of lutetium-177 (Lu) in European hospitals

P2860

Q36769707-159881E7-7806-4CE4-924E-A8DF63A110DD Q37674035-846C236F-437D-4CA7-B306-F41756534821 Q38918557-CF4A8E1A-E8D0-4BEF-9F3B-2F1259465F20 Q41896043-44FC492A-81B4-46B1-85CC-B94FFB46718A Q47114491-6FA3500B-CA46-4BD1-B5F2-87A0133CE321 Q47117558-7B2381B7-5A7B-4673-8511-EF614FE4BBAF Q47391185-A1A4339C-2465-456C-8AFF-025ED6A966A1 Q47731005-D9B2F8ED-7957-4E08-8ADF-3A8A2CBED898 Q50802390-B5CFC3FD-0660-40EC-8C3E-4AED2ED18BE4 Q55508871-5FA24745-0ADF-465D-857A-E2A7FD7B3B6E Q58803949-67AD2C33-89E1-4F80-9E91-B718F023A555

P2860

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

http://www.wikidata.org/entity/Q35724907

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

@ast

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

@en

type

label

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

@ast

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

@en

prefLabel

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

@ast

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

@en

P1433

Q35724907-6A3BC985-318A-4817-B577-12B1DDAC1CFB

P1476

Q35724907-BE9B32E6-136B-49B0-9ED6-7673EB92740B

P2093

Q35724907-81DB9024-C19D-48D2-A96F-707A69F4BC79

Q35724907-BAE41CC7-B0A7-4AC7-9A7E-84741BC8C4FE

P2860

Q35724907-04089B97-6435-4FAC-A12A-174852767C18

Q35724907-0A83779B-34EF-4578-BD87-B0E3861DEC62

Q35724907-0F751A8F-03CB-44BE-8262-6916346AC567

Q35724907-192DA532-1A47-479A-A72B-8B1E28A9A572

Q35724907-1DF18FC4-43F7-4EC9-9DC5-9FD6FAB632BF

Q35724907-2D491785-11F1-4358-BECC-2E1204502582

Q35724907-2F49254F-6134-49F3-AB88-AF2FD502AFF3

Q35724907-375CE5F2-E176-473A-A540-BE89E04A6E8F

Q35724907-3FF414BE-C987-4488-AA87-606E6D2A9AEE

Q35724907-40B4290D-9D5B-4A53-BC76-74BB1590AD4A

P2888

Q35724907-4FA483A6-4112-49A5-A906-72BEEC7A07FF

P304

Q35724907-EC9EC812-7828-473E-8F4B-4E28A3A2651E

P31

Q35724907-3D8F9281-6049-4D57-9B5E-6136D1DECD1A

P356

Q35724907-DAE199BB-F646-4614-9D88-069BD107F5C9

P433

Q35724907-8707B510-A151-4E31-80B4-CB2C1803DCFB

P478

Q35724907-0E948DC2-C509-483A-A6B7-CFF4A1CFC55B

P50

Q35724907-98F1F514-3B58-409D-BC6F-6131E3717A47

P577

Q35724907-644CA6D1-F13B-4629-953E-888F7BD28682

P5875

Q35724907-3DD40EC0-EE42-434D-8767-0ECBF96B40CE

P698

Q35724907-A55F8E13-6A55-47B3-8869-3693898D5D0A

P932

Q35724907-25A7CBC9-F26D-4503-8336-5F17DF0ADB2F

P356

S13139-014-0315-Z

P1433

Nuclear medicine and molecular imaging NMMI

P1476

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

@en

P2093

Furn F Knapp

http://www.w3.org/2001/XMLSchema#string

Maroor Raghavan Ambikalmajan Pillai

http://www.w3.org/2001/XMLSchema#string

P2860

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas.

Preparation and pre-clinical study of 177Lu-labelled hydroxyapatite for application in radiation synovectomy of small joints.

Therapeutic radiopharmaceuticals.

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.

Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.

Separation of transplutonium elements.

Therapeutic radionuclides: production and decay property considerations.

P2888

s13139-014-0315-z

P304

85-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13139-014-0315-Z

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273132630

http://www.w3.org/2001/XMLSchema#string

P698

26085854

http://www.w3.org/2001/XMLSchema#string

P932

4463871

http://www.w3.org/2001/XMLSchema#string